) recently announced that data from its phase II study on its
amyotrophic lateral sclerosis (ALS) candidate, tirasemtiv, was
published in the Amyotrophic Lateral Sclerosis and Frontotemporal
Last month, Cytokinetics provided an update on BENEFIT-ALS
(Blinded Evaluation of Neuromuscular Effects and Functional
Improvement with Tirasemtiv in ALS).
The company had reported a programming error in the
multinational, double-blind, randomized, placebo-controlled study
which is evaluating the safety, tolerability and efficacy of
Cytokinetics' data management vendor reported that due to a
programming error in the electronic data capture system
controlling study drug assignment, 58 patients received placebo
instead of tirasemtiv at a certain study visit.
The company said that no incorrect treatment was conducted on
the patients in the placebo arm.
Cytokinetics also conducted an ad hoc meeting of the study's
Data Safety Monitoring Board (DSMB) to determine determine that
the safety of the 58 patients affected by the error had not been
impacted. The DSMB reviewed the safety data and reported that
there were no concerns regarding patient safety.
Cytokinetics was also in the news for its collaboration with
Astellas Pharma, Inc.
) for the research, development and commercialization of skeletal
The companies will focus on identifying new treatments for
diseases and medical conditions related to muscle weakness. This
collaboration will combine Cytokinetics' expertise in the
discovery and mechanistic biology of small molecule activators of
skeletal muscle contractility with Astellas' capabilities in
discovery, development, and commercialization.
Cytokinetics currently carries a Zacks Rank #2 (Buy). At
present, companies like
Gilead Sciences Inc.
Jazz Pharmaceuticals Public Limited Company
) also look well-positioned with a Zacks Rank #1 (Strong Buy) and
a Zacks Rank #2 (Buy), respectively.
ASTELLAS PHARMA (ALPMY): Get Free Report
CYTOKINETCS INC (CYTK): Free Stock Analysis
GILEAD SCIENCES (GILD): Free Stock Analysis
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
To read this article on Zacks.com click here.